Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...

Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

Related: Bristol Myers's stock pops as earnings top estimates and company raises guidance In September, Bristol Myers's shares rose after the FDA approved Cobenfy. The drug, previously called KarXT, ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Investing.com - AbbVie (NYSE: ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...

Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Bristol-Myers Squibb Company PFD CONV 2 (OTCPK:BMYMP) had declared $0.50/share quarterly dividend Payable Dec. 2; for shareholders of record Nov. 5; ex-div Nov. 5. See BMYMP Dividend Scorecard, Yield ...

Compounding pharmacies are typically allowed to make copies of drugs that are deemed to be in shortage by the FDA, which semaglutide has been for over two years. But Novo argued that semaglutide ...

In September, the FDA approved the drug previously known as KarXT as a novel antipsychotic therapy for adults with schizophrenia. Citing new topline data from its 52-week open-label studies ...

Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...